Hyep Ivan, serving as the Chief Financial Officer for Bicara Therapeutics Inc. (NASDAQ:BCAX), has disposed of 9,200 shares of the company's common stock. The sale took place on April 21, 2026, resulting in a total transaction value of $211,613. According to reported data, the shares were sold at a weighted average price of $23.0015 per share. Individual prices for these transactions fluctuated within a range between $22.68 and $23.50.
This specific divestment was not an ad hoc decision but was conducted pursuant to a Rule 10b5-1 trading plan. Mr. Ivan had originally adopted this regulatory framework on February 13, 2025, to govern his future trades. The timing of this sale coincides with the stock's position near its 52-week high of $24.25. Over the preceding year, Bicara Therapeutics has seen a substantial return of 71%.
The liquidation was preceded by an acquisition of the same volume of shares. Mr. Ivan exercised stock options to acquire 9,200 shares at an exercise price of $3.7898 per share, representing a total cost of $34,866. These underlying options are subject to vesting in sixteen equal quarterly installments beginning after April 5, 2023, contingent upon Mr. Ivan's continued service with the firm.
Following these completed transactions, Mr. Ivan's direct holdings consist of 145,355 shares of Bicara Therapeutics common stock. Additionally, he maintains an interest in 39,744 derivative shares, which represent remaining stock options that are set to expire on April 5, 2033.
Corporate Context and Clinical Outlook
The insider activity occurs against a backdrop of recent financial reporting from Bicara Therapeutics. In its fourth-quarter 2025 financial results, the company noted a robust cash position alongside progress regarding its lead candidate, ficerafusp alfa. The firm has been providing updates on clinical trials targeting metastatic colorectal cancer as well as head and neck squamous cell carcinoma.
While the company has seen an increase in operating expenses, these developments have influenced investor sentiment. Market analysts have maintained positive outlooks for the company. Citizens reiterated a Market Outperform rating with a price target of $31, utilizing an analysis based on revenue multiples and discounted earnings per share. Similarly, H.C. Wainwright updated its price target for Bicara from $40 to $42 while keeping a Buy rating. This adjustment is supported by expected catalysts in 2026, including the presentation of Phase 1b study long-term follow-up data at ASCO 2026.